Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation

20 June 2018 | UCLB News

Fortress Biotech, formerly Coronado Biosciences Inc, announces publication in the journal Biology of Blood and Marrow Transplantation of positive Phase 1 clinical trial data evaluating technology licensed from UCLB, in the form of CNDO-109-activated allogeneic natural killer (NK) cells, in patients with acute myeloid leukemia (AML).

Learn more here: